Instructions for Berodual (Fenoterol + Ipratropium bromide) solution for inhalation
English product name
Berodual®
Release Form
Inhalation solution
Description Berodual
The inhalation solution is transparent, colorless or almost colorless, free from suspended particles, with an almost imperceptible smell.
1 ml
phenoterol hydrobromide 500μg
ipratropium bromide monohydrate 261μg,
in terms of anhydrous ipratropium bromide 250μg
Auxiliary substances: benzalkonium chloride, dihydrate edetate dihydrate dinatria, sodium chloride, 1n chlorohydric acid, water purified.
20 ml - bottles of dark glass with a polyethylene drip and a screwing polypropylene cap with the control of the first opening (1) - cardboard packs.
ATC codes Berodual
R03AL01 Phenoterol and ipratropium bromide
Clinical-pharmacological groups / Group affiliation
Broncholytic preparation
Active substance
- ipratropium bromide (anhydrous)
- phenoterol hydrobromide
Pharmaco-therapeutic group
Bronchodilating agent combined (m-cholinoblocker+beta2-adrenomimetic selective)
Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 25 ° C; do not freeze.
Best before date
The shelf life is three years.
Pharmacological effect Berodual
Combined broncholytic drug. It contains two components that have broncholytic activity: ipratropium bromide, m-cholinoblocker, and phenoterol hydrobromide, beta2-adrenomimetic.
Bronchodilation during inhalation of bromidine ipratropium is mainly due to local rather than systemic anticholinergic action.
Testimony Berodual
Prevention and symptomatic treatment of chronic obstructive airway diseases with reversible airway obstruction, such as bronchial asthma and especially COPD, chronic obstructive bronchitis with or without emphysema.
Method of use, course and dosage Berodual
Treatment should be performed under medical supervision (e.g. in hospital). Treatment at home is possible only after consultation with a doctor in cases where the fast-acting agonist of β-adrenoreceptors in a low dose is not effective enough. An inhalation solution may also be recommended to patients in cases where the inhalation aerosol cannot be used or if higher doses are necessary.
- Nosology (ICD codes)
- J43
- Emphysema
- J44
- Other chronic obstructive pulmonary disease
- J45
- Asthma
